CRVO with Macular Edema: What to Do When Intravitreal Anti-VEGF Therapy Has Not Achieved the Treatment Goals

Central retinal vein occlusion (CRVO) frequently causes macular edema — a major driver of vision loss in affected patients. When first-line intravitreal anti-VEGF treatment is not sufficient to achieve the expected clinical goals, a structured next-line approach is indicated.

Clinical scenario: CRVO complicated by macular edema, in a patient whose prior intravitreal anti-VEGF injections have not met the intended endpoints. In eyes with CRVO and macular edema, a patient is likely to develop persistent or recurrent edema requiring further intervention.

Previous line — goals not met

First-line therapy with intravitreal anti-VEGF agents — ranibizumab, aflibercept, faricimab-svoa, or bevacizumab — did not achieve the expected targets: reduction or resolution of macular edema and improvement or stabilization of visual function. Failure to reach these endpoints is the condition that escalates management to the protocol described here.

Next-line approach

This protocol centres on intravitreal corticosteroid therapy as the recognized next step when anti-VEGF treatment has been inadequate for macular edema in CRVO. The full agent selection, dosing pathway, and monitoring guidance are contained in the structured protocol…

Treatment goals: reduction or resolution of macular edema · improvement or stabilization of visual function

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.ophtha.2024.12.025

In eyes with CRVO and macular edema, anti-VEGF and intravitreal corticosteroids have demonstrated benefit.

A patient with a CRVO is likely to develop macular edema.

Intravitreal corticosteroids (triamcinolone and dexamethasone implant) are considered second line because of significant ocular side effects, such as secondary glaucoma and cataract formation.

Intravitreal corticosteroids such as triamcinolone, dexamethasone, and others have been shown to be efficacious for macular edema associated with BRVO and CRVO, yet there are known associated risks of cataracts and glaucoma.

View source ↗